Diabetic Retinopathy News and Research

RSS
In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
Researchers discover potential treatment for blinding disease

Researchers discover potential treatment for blinding disease

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy

Highlights of January 2010 'Ophthalmology'

Highlights of January 2010 'Ophthalmology'

Steroids not superior to laser treatments for DME

Steroids not superior to laser treatments for DME

Positive results from Alimera Sciences' Iluvien FAME trial for DME

Positive results from Alimera Sciences' Iluvien FAME trial for DME

Comprehensive up-date on pharmacology-assisted vitreoretinal surgery

Comprehensive up-date on pharmacology-assisted vitreoretinal surgery

Reference platform for diabetic retinopathy and other vascular complications

Reference platform for diabetic retinopathy and other vascular complications

Diabetes patients at higher risk from glaucoma

Diabetes patients at higher risk from glaucoma

ThromboGenics completes enrollment in second microplasmin Phase III trial

ThromboGenics completes enrollment in second microplasmin Phase III trial

Phase 1 clinical trial of iCo-007 demonstrates positive safety profile

Phase 1 clinical trial of iCo-007 demonstrates positive safety profile

iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

iCo Therapeutics to present an overview of its iCo-007 VEGF "+" agent at the ISOPT conference

Pycnogenol can improve microcirculation, retinal edema and visual acuity, reveals study

Pycnogenol can improve microcirculation, retinal edema and visual acuity, reveals study

New study indicates pine bark may reduce progressing advanced stages of diabetic retinopathy

New study indicates pine bark may reduce progressing advanced stages of diabetic retinopathy

Wnt signaling pathway plays a role in diabetic retinopathy

Wnt signaling pathway plays a role in diabetic retinopathy

Diabetic retinopathy on the rise; dilated eye exam can help prevent vision loss

Diabetic retinopathy on the rise; dilated eye exam can help prevent vision loss

ThromboGenics issues business update for the third-quarter of 2009

ThromboGenics issues business update for the third-quarter of 2009

Multicenter study finds AMD patients can benefit from cataract surgery

Multicenter study finds AMD patients can benefit from cataract surgery

Combination of inhibitor and antioxidants may help prevent diabetes complications

Combination of inhibitor and antioxidants may help prevent diabetes complications

Annual dilated eye exam helps prevent vision loss in people with diabetes

Annual dilated eye exam helps prevent vision loss in people with diabetes

CWRU grants licensing agreement to Bioptigen for FDOCT technology

CWRU grants licensing agreement to Bioptigen for FDOCT technology